Laniado-Laborín Rafael, Carrera-López Kenia, Hernández-Pérez Ana
Department of Respiratory Medicine, Autonomous University of Baja California School of Medicine and Psychology, Tijuana, Mexico.
Clinic of Tuberculosis, Tijuana General Hospital, Tijuana, México.
Turk Thorac J. 2018 Jun 19;19(4):226-227. doi: 10.5152/TurkThoracJ.2018.17062. Print 2018 Oct.
Several drugs used in the treatment of multidrug-resistant tuberculosis (MDR-TB) have been reported as teratogenic. Treatment of such cases during gestation is disputable. Some experts favor the termination of pregnancy, whereas others suggest reducing the dose of teratogenic drugs or even suspending the regimen during pregnancy. There have been no clinical trials on the subject, but case reports and case series show excellent outcomes for children exposed during pregnancy to second-line agents, indicating that aggressive management of gestational MDR-TB may benefit not only the mother but also the fetus. We present a case of pregnancy in a teenager while she was under treatment for MDR-TB and continued with full treatment and nevertheless delivered a healthy child.
据报道,几种用于治疗耐多药结核病(MDR-TB)的药物具有致畸性。妊娠期此类病例的治疗存在争议。一些专家倾向于终止妊娠,而另一些专家则建议减少致畸药物的剂量,甚至在孕期暂停治疗方案。目前尚无关于该主题的临床试验,但病例报告和病例系列显示,孕期接触二线药物的儿童预后良好,这表明积极治疗妊娠期耐多药结核病不仅可能使母亲受益,也可能使胎儿受益。我们报告一例青少年在接受耐多药结核病治疗期间怀孕,并继续接受全程治疗,最终产下一名健康婴儿的病例。